Are dual and triple incretin drugs ready for personalized health recommendations?

The core trade-off: one drug can't do everything

The central controversy is whether a single dual or triple incretin drug can be the 'best' choice for all patients, or whether different drugs will need to be matched to different patient priorities. The evidence so far says the latter: each drug excels in a different area. In a 2025 network meta-analysis of randomized controlled trials, tirzepatide (a dual GLP-1/GIP agonist) was the most effective at lowering fasting blood glucose (by an average of 57.3 mg/dL) and HbA1c (by 1.88 percentage points) [1]. But retatrutide (a triple GLP-1/GIP/glucagon agonist) produced the greatest weight loss—an average of 8.6 kg more than standard therapy [1]. A separate mouse study of diabetic kidney disease confirmed this pattern: tirzepatide was best for blood glucose control, while retatrutide was superior for weight loss and kidney function improvement [2]. So the trade-off is clear: you can't maximize both glucose lowering and weight loss with the same drug—the choice depends on the patient's primary need.

Where studies agree: triple agonists offer broader benefits, but with more side effects

Multiple studies converge on the idea that adding glucagon receptor activation (as in triple agonists like retatrutide) unlocks additional metabolic benefits beyond what GLP-1 alone can achieve. In obese mice, retatrutide boosted energy expenditure on top of reducing calorie intake, leading to greater total weight loss [4]. In diabetic mice, retatrutide also improved liver function, lowered triglycerides and cholesterol, and increased beneficial gut bacteria (butyrate) more than the other drugs tested [2]. And in humans with fatty liver disease (MASLD/MASH), dual and triple agonists are showing promise for improving liver inflammation and fibrosis, likely through weight loss and improved insulin resistance [3][5]. However, this broader efficacy comes with a cost: the 2025 meta-analysis found that tirzepatide increased the risk of any adverse event by 15%, and cotadutide (a dual GLP-1/glucagon agonist) by 38%, compared to standard therapy [1]. Only semaglutide (a single GLP-1 agonist) reduced the risk of serious adverse events (by 65%) [1]. So the pattern is consistent: more receptor targets = more potential benefit, but also more side effects.

Where evidence conflicts or falls short: not enough data for personalized recommendations

Despite the promising results, the evidence is not yet strong enough to support personalized health recommendations—that is, to say 'this drug for this patient type.' The 2025 meta-analysis itself notes limitations: small sample sizes, short study durations, and reliance on indirect comparisons (not head-to-head trials) [1]. Direct head-to-head trials are needed to confirm which drug works best for which patient subgroup. There is also unresolved debate about the optimal ratio of glucagon to GIP to GLP-1 activity in combination drugs, and even whether GIP should be activated or blocked for best results [5]. Additionally, while retatrutide showed superior kidney and liver benefits in mice, human data on these outcomes is still emerging [2][3]. One study explicitly states that the dominant mode of action of these drugs is likely 'upstream'—through weight loss—rather than direct organ effects, which means patients who don't lose much weight may not see the same benefits [5]. Until larger, longer, head-to-head human trials are completed, personalized prescribing remains a research aspiration, not a clinical reality.

About These Sources

This answer is built on 5 peer-reviewed studies — published from 2022 to 2025, 3 from 2024 or later, 3 in Q1 journals, collectively cited 433 times — selected as the most relevant from 5 studies that passed quality screening, drawn from 39 papers retrieved from a database of over 500 million.

Sources used in this answer

Related research questions